Mar 13, 2026
The FDA launched the Adverse Event Monitoring System (AEMS), consolidating seven legacy databases into a single platform with real-time reporting. The system is expected to save $120 million over five years while improving public access to safety data.
Mar 12, 2026
Federal vaccine advisers have dropped a plan to reconsider mRNA COVID-19 vaccine recommendations amid Republican concerns about midterm election impacts. The committee maintains its September 2025 decision on shared clinical decision-making.
Mar 12, 2026
New research from 18 countries shows COVID-19 vaccination during pregnancy, particularly with booster doses, significantly reduces the risk of preeclampsia and other serious complications for both mothers and babies.
Mar 07, 2026
Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will depart the agency by the end of April to return to an academic role at the University of California San Francisco.
Mar 03, 2026
Acurx Pharmaceuticals will discuss full year and fourth quarter 2025 financial results on March 13, 2026, and provide updates on ibezapolstat, its lead antibiotic candidate preparing for international Phase 3 trials for C. difficile infection.
Mar 03, 2026
Health Secretary Robert F. Kennedy Jr. is drawing criticism from anti-vaccine supporters who believe he has not gone far enough in dismantling vaccine programs, following regulatory reversals including the restoration of an mRNA flu shot review.
Feb 27, 2026
The American Medical Association and University of Minnesota's Vaccine Integrity Project are creating an independent vaccine review system after major changes at the CDC raised concerns among public health experts.
Feb 25, 2026
The U.S. recorded 2,280 measles cases in 2025, the highest since 1991, with 982 cases already confirmed in early 2026. North London faces an outbreak with 34 children infected in Enfield, while Philadelphia issued an exposure alert for the international airport.
Feb 25, 2026
The CDC's vaccine advisory committee meeting scheduled for February 25-27 has been canceled and rescheduled for March 18-19, as medical groups challenge the panel's composition and policies under Health Secretary Robert F. Kennedy Jr.
Feb 24, 2026
Ralph Abraham resigned as CDC principal deputy director after less than two months, leaving the agency's top two positions vacant. The departure is part of broader HHS leadership changes under Secretary Robert F. Kennedy Jr.
Feb 19, 2026
National Institutes of Health Director Jay Bhattacharya will serve as acting director of the Centers for Disease Control and Prevention following Jim O'Neill's departure. Bhattacharya will oversee both agencies simultaneously as the CDC faces significant instability.
Feb 17, 2026
The FDA has agreed to review Moderna's mRNA influenza vaccine application after initially rejecting it, following modifications by the company. A decision is expected by August 5, 2026.
Feb 18, 2026
The FDA agreed to review Moderna's mRNA-based flu vaccine after initially rejecting the application, following a Type A meeting that led to a revised regulatory approach splitting approval pathways by age group.
Feb 17, 2026
Recent studies reveal significant barriers in accessing mental health care for children and maternal health services, with nearly 25% of children's mental health needs going unmet and abortion restrictions linked to increased maternal deaths.
Feb 16, 2026
The FDA reversed its initial rejection and will now review Moderna's mRNA-based flu vaccine application after the company proposed a revised regulatory approach, targeting approval by August 2026.
Feb 17, 2026
The FDA agreed to review Moderna's mRNA-based flu vaccine after initially refusing, accepting a split regulatory approach with traditional approval for ages 50-64 and accelerated approval for 65 and older. Decision date set for August 5, 2026.
Feb 16, 2026
Artificial intelligence is advancing cancer care through early detection tools and improved clinical trial predictions. A Carnegie Mellon spinout is developing AI to identify high-risk patients, while predictive analytics are helping pharmaceutical companies prioritize promising compounds in oncology trials.
Feb 16, 2026
Health and Human Services Secretary Robert F. Kennedy Jr. announced the FDA will act on a petition to revoke GRAS status for dozens of processed sweeteners and starches, including corn syrup, unless companies prove they are safe.
Feb 14, 2026
The CDC is investigating a multistate outbreak of extensively drug-resistant Salmonella Newport with an NDM-1 gene linked to Rosabella moringa powder capsules, marking the first documented outbreak of Salmonella with an NDM-1 gene in the United States.
Feb 13, 2026
CDC and FDA are investigating a multistate outbreak of extensively drug-resistant Salmonella Newport infections linked to Rosabella brand moringa powder capsules, with seven people sickened across seven states and three requiring hospitalization.